Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC6 | Q9UBN7 | 4/20 | 1.00 |
| ▸ | TOP1 | P11387 | 3/20 | 0.64 |
| ▸ | TERT | O14746 | 1/20 | 0.60 |
| ▸ | MAPT | P10636 | 2/20 | 0.59 |
| ▸ | SNCA | P37840 | 1/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.58 |
| ▸ | CA12 | O43570 | 2/20 | 0.58 |
| ▸ | CA1 | P00915 | 2/20 | 0.58 |
| ▸ | CA2 | P00918 | 2/20 | 0.58 |
| ▸ | CA7 | P43166 | 2/20 | 0.58 |
| ▸ | CA9 | Q16790 | 2/20 | 0.58 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.58 |
| ▸ | GAA | P10253 | 2/20 | 0.58 |
| ▸ | POLB | P06746 | 1/20 | 0.58 |
| ▸ | CA4 | P22748 | 1/20 | 0.58 |
| ▸ | CA6 | P23280 | 1/20 | 0.58 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.58 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.58 |
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.55 |
| ▸ | XDH | P47989 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18346609 | 1.00 | HDAC6 (1.00) | HDAC6TOP1TERTMAPTSNCA | |
| SCHEMBL4362534 | 0.84 | HDAC6 (0.72) | HDAC6TOP1TERTMAPTSNCA | |
| SCHEMBL27828053 | 0.84 | HDAC6 (0.72) | HDAC6TOP1TERTMAPTSNCA | |
| SCHEMBL5924546 | 0.81 | HDAC6 (0.68) | HDAC6TOP1KDM4EEGLN2HDAC1 | |
| SCHEMBL14880111 | 0.81 | HDAC6 (0.68) | HDAC6KDM4EEGLN2HDAC1HDAC2 | |
| SCHEMBL31472702 | 0.80 | HDAC6 (0.67) | HDAC6TOP1TERTMAPTSNCA | |
| SCHEMBL9140722 | 0.80 | HDAC6 (0.67) | HDAC6TOP1TERTMAPTSNCA | |
| SCHEMBL328702 | 0.80 | HDAC6 (0.67) | HDAC6TOP1TERTMAPTSNCA | |
| SCHEMBL2664433 | 0.80 | HDAC6 (0.67) | HDAC6TOP1TERTMAPTSNCA | |
| SCHEMBL5488163 | 0.79 | HDAC6 (0.66) | HDAC6KDM4ECA12CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 178 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1017353-B1 | THERAPEUTIC PROCESS FOR INHIBITING NF-KAPPA B | ELFORD HOWARD L (US) | 2012-03-07 | — | — | EP | claimed |
| US-8029815-B2 | Methods for treating or preventing restenosis and other vascular proliferative disorders | ELFORD HOWARD L | 2011-10-04 | — | — | US | claimed |
| US-7977383-B2 | Containing alkali ions, electrolytes, a buffer, polyol, saccharide and hydroxamic acid derivatives | DR. FRANZ KOEHLER CHEMIE GMBH (DE) | 2011-07-12 | — | — | US | claimed |
| CN-100448440-C | Protective solution for preventing local ischemic damage | FRANTZ KOLER DR CHEMICAL GMBH (DE) | 2009-01-07 | — | — | CN | claimed |
| US-20080050414-A1 | Methods For Treating Or Preventing Restenosis And Other Vascular Proliferative Disorders | ELFORD HOWARD L | 2008-02-28 | — | — | US | claimed |
| EP-1744761-A1 | METHODS FOR TREATING OR PREVENTING RESTENOSIS AND OTHER VASCULAR PROLIFERATIVE DISORDERS | Molecules for Health, Inc. (US) | 2007-01-24 | — | — | EP | claimed |
| WO-2005115405-A1 | METHODS FOR TREATING OR PREVENTING RESTENOSIS AND OTHER VASCULAR PROLIFERATIVE DISORDERS | MOLECULES FOR HEALTH, INC. (US) | 2005-12-08 | — | — | WO | claimed |
| US-6924308-B1 | Therapeutic process for inhibiting NF-κB | MOLECULES FOR HEALTH, INC. | 2005-08-02 | — | — | US | claimed |
| EP-1017353-A4 | THERAPEUTIC PROCESS FOR INHIBITING NF-KAPPA B | ELFORD HOWARD L (US) | 2005-02-23 | — | — | EP | claimed |
| US-20040228839-A1 | Composition and methods for treatment of HIV infection | AVRAMIS VASSILIOS I (US) | 2004-11-18 | — | — | US | claimed |
| US-5366996-A | Administering hydroxamic acids | ELFORD HOWARD L (US) | 1994-11-22 | — | — | US | claimed |
| US-5350770-A | Administering hydroxy benzamide derivative | ELFORD HOWARD L (US) | 1994-09-27 | — | — | US | claimed |
| EP-0610444-A1 | METHOD OF TREATING VIRAL DISEASES | ELFORD, Howard L. (US) | 1994-08-17 | — | — | EP | claimed |
| WO-1994002135-A1 | THERAPEUTIC PROCESS FOR THE TREATMENT OF SEPTIC SHOCK | ELFORD HOWARD L (US) | 1994-02-03 | — | — | WO | claimed |
| WO-1993012782-A1 | METHOD OF TREATING VIRAL DISEASES | ELFORD HOWARD L (US) | 1993-07-08 | — | — | WO | claimed |
| EP-0140958-B1 | ONCOLYTIC DRUG COMBINATIONS | ELFORD, Howard L. (US) | 1989-12-20 | — | — | EP | claimed |
| EP-0140958-A4 | ONCOLYTIC DRUG COMBINATIONS. | ELFORD HOWARD L (US) | 1985-09-02 | — | — | EP | claimed |
| EP-0140958-A1 | ONCOLYTIC DRUG COMBINATIONS. | ELFORD HOWARD L (US) | 1985-05-15 | — | — | EP | claimed |
| WO-1984004246-A1 | ONCOLYTIC DRUG COMBINATIONS | ELFORD HOWARD L | 1984-11-08 | — | — | WO | claimed |
| US-4394389-A | ANTITUMOR AGENTS | RIET BARTHOLOMEUS VAN T | 1983-07-19 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080050414-A1 | Methods For Treating Or Preventing Restenosis And Other Vascular Proliferative Disorders | RRM2B, PCNA, RRM2 | HDAC6 1927/4885TOP1 255/4885TERT 1608/4885 |
| US-20040228839-A1 | Composition and methods for treatment of HIV infection | ASNS, RNASE1, RNASEH1 | HDAC6 1365/4885TOP1 1277/4885TERT 1332/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.